Targeted Therapies for Melanoma
Open Access
Abstract
The incidence of cutaneous malignant melanoma (CMM) is significantly increasing worldwide.Keywords
This publication has 15 references indexed in Scilit:
- Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review)International Journal of Oncology, 2020
- Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole CompoundsCancers, 2020
- RKIP Regulates Differentiation-Related Features in Melanocytic CellsCancers, 2020
- Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted TherapiesCancers, 2020
- FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated MelanomaCancers, 2020
- TERT Promoter Mutations Differently Correlate with the Clinical Outcome of MAPK Inhibitor-Treated Melanoma PatientsCancers, 2020
- Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic MelanomaCancers, 2020
- Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of ResistanceCancers, 2020
- ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine NeuregulinCancers, 2019
- Years of life lost as a measure of cancer burden on a national levelBritish Journal of Cancer, 2014